Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Telavancin
Drug ID BADD_D02143
Description Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.
Indications and Usage For the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria like methicillin-susceptible or -resistant Staphylococcus aureus, vancomycin-susceptible Enterococcus faecalis, and Streptococcus pyogenes, Streptococcus agalactiae, or Streptococcus anginosus group. Also for the treatment of adult patients with hospital-acquired bacterial pneumonia (HAP) and ventilator-associated bacterial pneumonia (VAP), known or suspected to be caused by susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant S. aureus).
Marketing Status approved
ATC Code J01XA03
DrugBank ID DB06402
KEGG ID D06057
MeSH ID C487637
PubChem ID 3081362
TTD Drug ID D0B9JO
NDC Product Code 71124-0005
UNII XK134822Z0
Synonyms telavancin | TD 6424 | TD6424 | TD-6424 | Vibativ | telavancin hydrochloride
Chemical Information
Molecular Formula C80H106Cl2N11O27P
CAS Registry Number 372151-71-8
SMILES CCCCCCCCCCNCCNC1(CC(OC(C1O)C)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)N C(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl) O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
International normalised ratio increased13.01.02.008--
Laryngeal pain22.12.03.010--
Leukopenia01.02.02.001---
Malaise08.01.01.003--
Microalbuminuria05.07.02.002; 14.07.02.002; 20.02.01.026---
Migraine17.14.02.001; 24.03.05.003---
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nephropathy toxic12.03.01.010; 20.05.03.002---
Nervous system disorder17.02.10.001---
Neutrophil count increased13.01.06.011---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Oliguria20.01.03.004---
Pain08.01.08.004--
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.094--
Parosmia17.04.04.002; 22.04.03.007---
Phlebitis12.02.01.002; 24.12.03.004--
Pollakiuria20.02.02.007--
Pruritus23.03.12.001--
Rash23.03.13.001---
Renal failure20.01.03.005---
Septic shock11.01.11.004; 24.06.02.011---
Sinus tachycardia02.03.03.010--
Skin disorder23.03.03.007---
Somnolence17.02.04.006; 19.02.05.003--
Supraventricular extrasystoles02.03.03.011---
Thrombocytopenia01.08.01.002---
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages